Health and Fitness Health and Fitness
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ] - Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
Thu, September 2, 2010

Inspire Announces Webcasts of Presentations at the UBS Global Life Sciences Conference and the JMP Securities Healthcare Confer


//health-fitness.news-articles.net/content/2010/ .. ce-and-the-jmp-securities-healthcare-confer.html
Published in Health and Fitness on Tuesday, September 14th 2010 at 3:40 GMT by Market Wire   Print publication without navigation


DURHAM, N.C.--([ BUSINESS WIRE ])--Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Adrian Adams, President and CEO, will present at the UBS Global Life Sciences Conference on Tuesday, September 21, 2010 at 9:00 am ET and at the JMP Securities Healthcare Conference on Monday, September 27, 2010 at 12:00 pm ET in New York City.

The webcasts of the presentations will be available on Inspirea™s website at [ www.inspirepharm.com ]. Archived versions of the webcast presentations will also be available through this link for a limited time following the conference.

About Inspire

Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspirea™s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. Inspirea™s clinical pipeline includes denufosol tetrasodium for cystic fibrosis in Phase 3 development and AZASITE®(azithromycin ophthalmic solution) 1% for blepharitis in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. For more information, visit [ www.inspirepharm.com ].


Publication Contributing Sources